Q-omics provides the consensus-scored OR6C4 profile across patient tissues and cancer cell-line models. OR6C4 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in SARC. Among the 18 cancer types available for tumor–normal comparison, OR6C4 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, OR6C4 RNA expression shows 3,628 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SARC, PRAD, and STAD as cancer lineages where OR6C4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR6C4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR6C4 survival associations across molecular data types. OR6C4 RNA expression shows survival associations in the most cancer types (9), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR6C4 RNA expression–survival associations across cancer types. High OR6C4 expression shows unfavorable associations in SARC, PAAD, UCEC, THCA and KIRC, but favorable associations in SKCM. The SARC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SARC as the clearest survival context for OR6C4 RNA expression.
This table summarizes OR6C4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR6C4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR6C4 shows higher tumor expression in PRAD. The PRAD box plot shows higher OR6C4 RNA expression in tumor versus normal tissue (log2 FC = +0.005, t-test p = .042).
This table shows molecular features associated with OR6C4 in patient tissues and cancer cell lines. In patient samples, OR6C4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR6C4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
